论文部分内容阅读
目的:探讨以多西他赛为基础的化疗药物与BRCA-1mRNA在胃癌个体化治疗中的相关性。方法:采用实时荧光定量逆转录聚合酶链反应检测74例胃癌患者组织标本中BRCA-1mRNA的表达水平,比较其与接受不同化疗方案患者生存情况之间的关联。结果:BRCA-1mRNA低表达者42例(56.76%),高表达者32例(43.24%),BRCA-1mRNA表达水平与临床病理特征无关(P>0.05)。BRCA-1mRNA高表达者经多西他赛辅助化疗后其中位总生存期显著长于低表达者(48.1vs11.1个月,P=0.009);高表达者的无疾病生存期长于低表达患者(25.1vs7.1个月,P=0.038)。Cox多因素回归分析显示,BRCA-lmRNA表达水平是影响胃癌患者预后的独立因素。在使用奥沙利铂的22例患者中,BRCA-1mRNA低表达患者中位总生存期长于高表达患者(40.8vs17.3个月,P=0.556);低表达患者无疾病生存期长于高表达患者(33.1vs10.5个月,P=0.345)。结论:BRCA-1mRNA表达水平可作为接受多西他赛化疗的胃癌患者预后的独立预测因素。
Objective: To investigate the correlation between docetaxel-based chemotherapeutic drugs and BRCA-1? MRNA in the individualized treatment of gastric cancer. Methods: The expression of BRCA-1 mRNA in tissue samples of 74 patients with gastric cancer was detected by real-time fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR), and compared with the survival of patients receiving different chemotherapy regimens. Results: There were 42 cases (56.76%) with low expression of BRCA-1? MRNA and 32 cases (43.24%) with high expression of BRCA-1? MRNA. The expression of BRCA-1? MRNA was not correlated with the clinicopathological features (P> 0.05). The median overall survival of patients with BRCA-1 mRNA overexpression after docetaxel adjuvant chemotherapy was significantly longer than those with low expression (48.1 vs 11.1 months, P = 0.009). Patients with high expression had longer disease-free survival than those with low Patients were expressed (25.1? Vs? 7.1 months, P = 0.038). Cox regression analysis showed that BRCA-1 mRNA expression level was an independent factor affecting the prognosis of patients with gastric cancer. Among the 22 patients who received oxaliplatin, median overall survival was longer in patients with low BRCA-1 mRNA expression (40.8 vs 17.3 months, P = 0.556); patients with low expression had no disease-free survival Longer than those with high expression (33.1? Vs? 10.5 months, P = 0.345). Conclusion: The expression level of BRCA-1? MRNA may be used as an independent predictor of the prognosis of gastric cancer patients receiving docetaxel chemotherapy.